

IN THE LINE DISTATES PATENT AND TRADEMARK OFFICE

In re Application of:	
LIANG ET AL.) Group Art No: Unassigned
Serial No: 10/070560) Examiner: Unassigned
Filed: March 8, 2002)
For: METHOD OF PRODUCING AND PURIFYS ENDOSTATIN PROTEIN) ING))
	(1)

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, DC 20231

Sir:

The citation of information on the attached Form PTO/SB/08A, "List of Art Cited by Applicant" is made pursuant to 37 C.F.R. §§ 1.97 and 1.98. A copy of all listed items is enclosed. The citation of this information does not constitute an admission that any of the materials are available as a reference or of priority, or a waiver of any right applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,

By: Theodore M. Green

Reg. No. 41,801

KILPATRICK STOCKTON LLP

Suite 2800 1100 Peachtree Road Atlanta, Georgia 30309 (404) 815-6500

Our Docket: 05213-0551US (43170-258385)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC, 20231, on Jung-6;7002

Theodore M. Green – Reg. No. 41,801

PTO/SB/08A (08-00)

Approved for use through 1031/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U PARATMENT OF COMMENCE
Under the Paperwork Reduction Act of 1967 to 1 Paratment of the Comment of the

Substitute for Form 1449/A/PTO

Sheet

INFORMATION DISCUSSIVE STATEMENT BY APPLICANT (use as many sheets as necessary) Complete if Known
Application No. 10/070560
Filing Date 11/30/2001
First Named Inventor Liang et al.
Group Art Unit Not Yet Assigned
Examiner Name Unassigned
Attomey Docket Number 02/31-9/51 US/43/170-258855)

1 of 3 Attorney

U.S. PATENT DOCUMENTS U.S. Patent Document Date of Publication Pages, Columns, Lines, Where Examiner Cite Kind Code⁵ Name of Patentee or of Cited Document Relevant Passages or Initials No.1 Number⁴ (if known) Applicant of Cited Document MM-DD-YYYY Relevant Figures Appear 5.854.205 O'Reilly et al. 12/29/1998 1

Examiner Signature	Date Considered	

PTO/SB/08A (08-00)

U.S. Patent and Trademark Office: U.S. Department of the Community of the

JUN 1 1 2002 6

Substitute for Form 1449/A/PTO

2

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

3

Complete it					
Application No.	10/070560				
Filing Date	03/08/2002				
First Named Inventor	Liang et al.				
Group Art Unit	Unassigned				
Examiner Name	Unassigned				
Attorney Docket Number	05213-0551US(43170-258385)				

FOREIGN PATENT DOCUMENTS								
Examiner Initials Cite No. Office Number (if known)			Kind Code ³	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T	
	2	wo	96/08274	A2	Prizm Pharmaceuticals, Inc.	03/21/1996		
	3	wo	99/26480	A1	Genetix Pharmaceuticals, Inc. and MIT	06/03/1999		Γ

Examiner Signature	Date Considered	

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE respond to a collection of information Under the Paperwork Reduction Act of 19 s it contains a valid OMB control number Con

Substitute for Form 1449/A/PTO	JUN 1 1 2002
INFORMATION DI	
STATEMENT BY A	
(nce as many cheets as n	ececcaru)

of

3

Sheet

if Known Application No. 10/070560 Filing Date 03/08/2002 First Named Inventor Liang et al. Group Art Unit Unassigned Examiner Name Unassigned Attorney Docket Number 05213-0551US(43170-258385)

		Include name of the author (in C	APITAL LETTERS) title of the article (s	when appropriate) title of	the		Г
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published					Т	
	4		Title: Disruption of the KEX1 Gene in <i>Pichia pastoris</i> Allows Expression of Full-Length Murine and Human Endostatin					Γ
		Yeast		Vol/iss: 15	Pages: 563-572	Date:	1999	
	5	Author: BOEHM ET AL. Title:	Zinc-Binding of Er	dostatin is Essential f	or Its Antiangiogenic Ac	tivity		Ī
		Biochemical and Biophysical Research Commu	nications	Vol/iss: 252	Pages: 190-194	Date:	1998	L
	6	Author: DHANABAL ET AL. Title: Publ:	Endostatin: Yeast I	roduction, Mutants, a	and Antitumor Effect in R	enal Cell	Carcinoma	
		Cancer Research		Vol/lss: 59	Pages: 189-197	Date:	01/01/199	L
	7			Forms of Human Pla Fragments of Collage	asma Endostatin and Circ en XV	ulating		Ē
		Biochemistry		Vol/iss: 38 (32)	Pages: 10217-10224	Date:	08/10/199	
	8			ion Broth: Expanded	lostatin and Angiostatin f Bed Adsoption Chromato			Ī
		Abstracts of Papers American Chemical Society		Vol/lss: 219 (1-2)	Pages: BIOT 212	Date:	03/26/200	L
	9	Author: STANDKER et al. Title:	Isolation and chara	cterization of the circ	ulating form of human en	dostatin		Γ

Examiner	Date	
Signature	Considered	l l

'Unique citation designation number. 'See attached Kinds of U.S. Patent Documents. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 'Applicant is to place a check mark here if English language translation is attached.